developing lsc-targeting agents in aml: progress and current therapeutic capacity
Published 3 months ago • 119 plays • Length 0:59Download video MP4
Download video MP3
Similar videos
-
4:27
antibody-based targeting of bcma in multiple myeloma
-
1:35
enhance-2 and enhance-3: exploring magrolimab combinations in aml
-
4:35
agmt mm 02: outcomes and time to best response in myeloma
-
1:18
an insight into the challenges in prolonging remission in aml
-
3:11
sequencing immunotherapies in multiple myeloma
-
3:15
what is the best diet for myeloma patients to build a strong immune system?
-
10:42
ep 40 - multiple myeloma update jan 2022 - revlimid - zometa side effects - dental work
-
2:59
what is multiple myeloma?
-
2:38
session highlights: transforming aml treatment and building on new approaches
-
2:17
extended follow-up of the master trial
-
0:56
overcoming the challenges in prolonging remission in aml
-
1:59
the role of upfront double auto-sct in high-risk myeloma
-
2:17
session highlights: practical aspects of immunotherapy in multiple myeloma
-
2:33
an update on antibody-based treatment approaches in multiple myeloma
-
2:58
long-term follow-up: phase ii study of apr-246 aza in tp53-mutated mds & aml
-
1:26
insight-mm study update: treatment patterns in first and second-line multiple myeloma
-
2:45
continuity of care for patients with hematological predispositions to aml
-
2:26
emerging immunotherapeutic strategies for multiple myeloma in the frontline and r/r settings
-
2:05
emerging therapeutic challenges to treating patients with multiple myeloma
-
5:06
advances in immunotherapy for multiple myeloma and future outlooks
-
1:42
optimal sequencing of immunotherapies to improve outcomes for patients with multiple myeloma
-
1:57
sequencing immunotherapies in multiple myeloma